drugset / Trial / NCT02365285

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285 ↗

RandomizedCrossoverDouble-blindTreatment

Summary

The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.

Timeline

Start
2015-03
Primary completion
2017-10-05
Completion
2017-10-05

Outcome

Met primary endpoint

paper Compared to placebo, 16 mg of galantamine significantly inhibited the increase in F2-IsoPs in PBMC (0.007 ± 0.008 vs. - 0.002 ± 0.006 ng/sample, P = 0.016) PMID 35659521 ↗

paper Compared to placebo, 16 mg of galantamine significantly inhibited the increase in F2-IsoPs in PBMC PMID 35659521 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 16 mg Oral
Background Heparin Other / unclassified 200 iu Intravenous
Background Intralipid Other / unclassified 0.8 ml Intravenous
Background Intralipid Other / unclassified 20 % Intravenous

Indications